Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Dr Eric Rackow Discusses the Role of Virtual Support for Family Caregivers
March 1st 2023Eric Rackow, MD, cofounder and executive chairman of eFamilyCare, discusses eFamilyCare's role for family caregivers and how the system can help overcome social determinants of health that may impact patient outcomes.
National Primary Care Scorecard Highlights Needs for Funding, Workforce Development, and Care Access
February 23rd 2023A newly published national report reveals a lack of financing, a shrinking workforce, gaps in care access, and nearly no federal funding for research within the US primary care space.
Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM
February 23rd 2023Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.
Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBC
February 22nd 2023Results from a phase 2 study suggests that the oncolytic virus talimogene laherparepvec has potential to improve therapy responses for patients undergoing neoadjuvant chemotherapy for triple-negative breast cancer (TNBC).
Study Characterizes Real-World Use of Relugolix in Combination With Other Prostate Cancer Therapies
February 19th 2023Relugolix was frequently used in combination with other medications for prostate cancer in patients both new to androgen-deprivation therapy and continuing androgen-deprivation therapy in a real-world study.
Study Suggests Second-line Axi-Cel Is Cost-effective vs Standard Care in R/R DLBCL
February 18th 2023Despite coming at a high cost, an analysis found that in some cases, chimeric antigen receptor T-cell therapy may be cost-effective compared with the standard of care in the second line or later for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Postdischarge Telemonitoring, Telephone Coaching May Benefit Certain Patients With Heart Failure
February 17th 2023Patients with heart failure and high comorbidity burdens who received postdischarge noninvasive telemonitoring and nurse telephone coaching showed better survival outcomes than those who received standard care.
Cancer Symptom Algorithm Identifies Patients at Greater Risk of ED Visits, Hospital Admissions
February 15th 2023A novel algorithm based on patient-reported outcome questionnaires stratified patients by disease complexity and effectively identified those at a higher risk of having an acute care visit.
Hyaluronic Acid Spacer May Reduce Rectal Dosimetry, GI Toxicity From Prostate Cancer Treatment
February 9th 2023A randomized controlled trial found that the use of a rectal spacer may help mitigate the gastrointestinal (GI) toxicity associated with hypofractionated radiation therapy for prostate cancer.
Dr Jeremy Abramson Discusses CAR T-Cell Therapy Timing in DLBCL
February 4th 2023Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at the Massachusetts General Hospital Cancer Center, shared his take on the potential benefits of chimeric antigen receptor (CAR) T-cell therapy in earlier lines of treatment.
FDA Approves Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer
February 3rd 2023The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.
Racial and Ethnic Disparities Persist in B-Cell ALL Survival in Children, Young Adults
February 3rd 2023Despite overall improvements in survival outcomes in recent decades, disparities in survival outcomes persist among children and young adults with acute lymphocytic leukemia (ALL) across racial and ethnic groups.
International Panel Forms Consensus Best Practices for Active Surveillance in Prostate Cancer
February 1st 2023Health care expert and lived experience panels came to a consensus on several aspects that should be considered in the decision to offer and continue active surveillance for prostate cancer.